|Articles|February 10, 2014

Certara Offers TQT Assessment Tool

Product helps to determine whether a drug candidate prolongs cardiac repolarization, a surrogate for potentially-fatal arrhythmias

Certara, which offers software and scientific consulting services for drug development, announced the launch of itsPhoenix QT+ cardiac safety assessment tool. This product provides data processing, statistical, and modeling capabilities in regard to Thorough QT (TQT) study requirements under the ICH E14 Guidelines (ICH, 2005). The product provides a comprehensive analysis of electrocardiogram (ECG) interval data collected in TQT studies and sub-studies in other clinical trials to determine whether a drug is at risk for cardiac depolarization prolongation.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Certara Offers TQT Assessment Tool

Related Content

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

A Shot in the Arm to Traditional Vaccine Trial Strategy

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention